Dendrons have well-defined
dendritic structures. However, it is
a great challenge to preserve their high structural definition after
multiple functionalization because the site-selective conjugation
of different functional molecules is quite difficult. Scaffold-modifiable
dendrons that have orthogonal reactive groups at the scaffold and
periphery are ideal for achieving the site-specific bifunctionalization.
In this paper, we present a new strategy for synthesizing scaffold-modifiable
dendrons via orthogonal amino protection and a solid-phase synthesis
method. This strategy renders the reactive sites at the scaffold and
periphery of the dendrons a super selectivity, high reactivity, and
wide applicability to various reaction types. The fourth-generation
dendrons can be facilely synthesized within 2 days without structural
defects as demonstrated by mass spectrometry. We conjugated doxorubicin
(DOX) and phenylboronic acid (PBA) groups to the scaffold and periphery,
respectively. Thanks to the PBA-enhanced lysosome escape, tumor targeting
ability, and tumor permeability as well as the high drug loading content
larger than 30%, the dendron-based prodrug exhibited extraordinary
antitumor efficacy and could eradicate the tumors established in mice
by multiple intravenous administration. This work provides a practical
strategy for synthesizing scaffold-modifiable dendrons that can be
a promising nanoplatform to achieve function integration in a precisely
controlled manner.